Drug details:
Molecular formula: C₂₃H₁₆Cl₂N₂O₄

Standard name: (5E)-5-[[5-(2,4-dichlorophenyl)furan-2-yl]methylidene]-1-(3,5-dimethylphenyl)-1,3-diazinane-2,4,6-trione

Curated SMILES: CC1=CC(=CC(=C1)N2C(=O)/C(=C/C3=CC=C(O3)C4=C(C=C(C=C4)Cl)Cl)/C(=O)NC2=O)C

Evidence for compound's anti-virulence activity:

Clostridium
Related VF: theta-toxin/PFO (Perfringolysin O)
Target: PfoA
Drug effect: Blocks Perfringolysin O (PFO)-binding to cholesterol-containing membranes and subsequent pore formation to prevent PFO-mediated cytolysis and cell death during infection.
Max phase: Preclinical (in vitro)
Publication:
Aziz UBA, et al., 2024. Targeted small molecule inhibitors blocking the cytolytic effects of pneumolysin and homologous toxins. Nat Commun 15(1):3537.

Streptococcus
Related VF: Pneumolysin
Target: Ply
Drug effect: Blocks Pneumolysin (PLY)-binding to cholesterol-containing membranes and subsequent pore formation to prevent PLY-mediated cytolysis and cell death during infection.
Max phase: Preclinical (in vitro)
Publication:
Aziz UBA, et al., 2024. Targeted small molecule inhibitors blocking the cytolytic effects of pneumolysin and homologous toxins. Nat Commun 15(1):3537.